SUPPORTIVE CARE A. Acute and Delayed Emesis Prophylaxis: The TP
regimen is predicted to have a low (10% to 30%) risk of causing nausea or vomiting. [16] [17] [18] [19] However, the studies reviewed reported nausea or vomiting in 41% 3 and vomiting in 6% to 21% 3, 4 of patients receiving weekly paclitaxel and nausea in 50% 3 and vomiting in 2% to 37% of patients 3, 5 receiving paclitaxel every 3 weeks, suggesting that the regimen may be more emetogenic than predicted. Prophylactic antiemetic therapy with dexamethasone or a serotonin antagonist alone may be suffi cient, particularly for patients receiving paclitaxel weekly. [17] [18] [19] Because dexamethasone is generally part of the hypersensitivity prophylaxis for paclitaxel, additional dexamethasone as part of the antiemetic regimen is not needed. One of the following regimens is recommended: every 3 weeks for 7 cycles. Trastuzumab was given 8 mg/kg the day after the fi rst paclitaxel dose, and then 6 mg/kg every 3 weeks on the same day as the paclitaxel dose. Trastuzumab was continued in responding patients until disease progression or patient withdrawal. 7 5. Gori et al used paclitaxel 60 to 90 mg/m 2 depending on prior treatment weekly for 6 months. Trastuzumab was given 4 mg/kg the day before the fi rst paclitaxel dose, and then 2 mg/kg weekly after paclitaxel. 9 6. John et al used paclitaxel 90 mg/m 2 weekly given over two 6-week blocks with a 14-day break. Trastuzumab was given as 4 mg/kg loading dose and then 2 mg/kg weekly thereafter. 11 The antiemetic therapy should continue for at least 3 days. A meta-analysis of several trials of serotonin antagonists recommends against prolonged (greater than 24 hours) use of these agents, making a steroid, or steroid and dopamine antagonist combination, most appropriate for follow-up therapy. 20 One of the following regimens is recommended: Patients who experience signifi cant nausea or vomiting with one of these regimens should receive an agent from a different pharmacologic category. [16] [17] [18] [19] There is no evidence that substituting granisetron for ondansetron in subsequent treatment cycles or increasing the dose, even to very high doses, is effective. This approach is not recommended. [21] [22] [23] [24] [25] B. Breakthrough Nausea and Vomiting [16] [17] [18] [19] : Patients should receive a prescription for an antiemetic to treat breakthrough nausea. One of the following regimens is suggested: A few small studies suggest that higher doses of granisetron (3 mg IV or 40 mcg/kg to 240 mcg/ kg) [21] [22] [23] [24] [25] may be effective in treating breakthrough nausea; however, none of these reports found the improvement to be statistically signifi cant. C. Hypersensitivity Precautions: Paclitaxel injection produces hypersensitivity reactions in about 10% of patients. 26, 27 Routine prophylactic premedications should be given prior to paclitaxel administration. The following regimen is suggested 28 : 1. Ranitidine 50 mg 2. Dexamethasone 10 or 20 mg 3. Diphenhydramine 50 mg All should be given IV over 30 minutes prior to paclitaxel. D. Hematopoietic Growth Factors: Accepted practice guidelines and pharmaco economic analysis suggest that antineoplastic regimens have a greater than 20% incidence of febrile neutropenia before prophylactic use of colony stimulating factors (CSF) is warranted. For regimens with an incidence of febrile neutropenia between 10% and 20%, use of CSF should be considered. For regimens with an incidence of febrile neutropenia less than 10%, routine prophylactic use of CSF is not recommended. 28, 29 Because severe (grade 3 or 4) neutropenia was reported in up to 15% 8 of patients in the TP trials reviewed and febrile neutropenia was reported in 1% 8 of patients, prophylactic use of CSF is not recommended with this regimen.
CSF should be considered if a patient experiences febrile neutropenia or grade 4 neutropenia in a prior cycle of TP.
MAJOR TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (http://evs. nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_ QuickReference_8.5x11.pdf). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities, but make, or consider making, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%. A. Weekly Paclitaxel (80 mg/m 2 )
